GlassScriptPhysician profile
Alisha J Cooley
NPI 1851699060
$2,026.07
in general payments reported to CMS, 2019-2025
29 companies · $656 in 2025
The $656 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $387 · 2022: $77.36 · 2023: $475 · 2024: $430 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $715.39 | 2021-2025 | |
| Lilly USA, LLC | $170.06 | 2022-2025 | Mounjaro, Omvoh, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.22 | 2021-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $93.77 | 2022-2023 | Trelegy Ellipta |
| Mylan Specialty L.P. | $82.37 | 2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $72.65 | 2021-2025 | Entyvio, Trintellix |
| Novartis Pharmaceuticals Corporation | $62.82 | 2022-2025 | |
| Astellas Pharma US INC | $57.36 | 2023-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.25 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $55.00 | 2023-2025 | Rexulti, Abilify Maintena |
| Nestle Healthcare Nutrition INC. | $54.23 | 2021 | |
| Pfizer INC. | $42.78 | 2021-2025 | |
| Cipher Pharmaceuticals US LLC | $39.95 | 2025 | Spinosad, Natroba |
| Astrazeneca Pharmaceuticals LP | $39.49 | 2024 | Airsupra |
| Alkermes, INC. | $36.45 | 2025 | Aristada, Lybalvi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $35.95 | 2024-2025 | Fanapt |
| Mylan Institutional INC. | $32.76 | 2023 | |
| Fresenius Kabi USA, LLC | $27.73 | 2023 | Idacio |
| Almatica Pharma LLC | $24.31 | 2024 | Loreev Xr |
| Medtronic, INC. | $22.62 | 2024 | Gi Genius |
| Regeneron Healthcare Solutions, INC. | $17.90 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.74 | 2023-2025 | Voquezna |
| Neurelis, INC. | $16.70 | 2024 | Valtoco |
| Ardelyx, INC. | $15.69 | 2023 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.34 | 2024 | Jardiance |
| Novo Nordisk INC | $15.25 | 2024 | Rybelsus, Ozempic |
| Ipsen Biopharmaceuticals, INC | $14.63 | 2025 | Iqirvo |
| Janssen Biotech, INC. | $14.52 | 2023 | Stelara |
| Qol Medical, LLC | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisha Cooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.